

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :	A2	(11) International Publication Number: WO 00/50064 (43) International Publication Date: 31 August 2000 (31.08.00)
A61K 38/21, A61P 31/14 // (A61K 38/21, 31:365) (A61K 38/21, 31:4164) (A61K 38/21, 31:517) (A61K 38/21, 31:13) (A61K 38/21, 31:505) (A61K 38/21, 31:7052)		
(21) International Application Number:	PCT/US00/04699	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	25 February 2000 (25.02.00)	
(30) Priority Data:		
60/121,931 26 February 1999 (26.02.99) US 60/181,068 8 February 2000 (08.02.00) US		
(71) Applicant ( <i>for all designated States except US</i> ): INSTITUTE OF MOLECULAR AND CELL BIOLOGY [SG/SG]; 30 Medical Drive, Singapore 117609 (SG).		
(72) Inventors; and		<b>Published</b>
(75) Inventors/Applicants ( <i>for US only</i> ): TAN, Yin, Hwee [CA/SG]; 30 Medical Drive, Singapore 117609 (SG). DRISCOLL, John, S. [US/US]; 4 Infield Court South, Rockville, MD 20854 (US).		Without international search report and to be republished upon receipt of that report.
(74) Agent: WILSON, Mary, J.; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).		

(54) Title: SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES

(57) Abstract

Flavivirus and rhabdovirus infections may be treated by administering an interferon such as interferon  $\alpha$ 2, interferon  $\alpha$ 8 or interferon  $\beta$  and at least one compound selected from 5-membered cyclic nucleosides, mycophenolic compounds, imidazole derivatives, aminoadamantanes and 2, 4-diaminopyrimidines.